Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 1, 2018
Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2018. Learn how to tune in.
-
Sep 24, 2018First peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease
Eluvia is the first peripheral vascular interventional technology approved in U.S. to offer a sustained release of a drug to treat peripheral artery disease.
-
Sep 22, 2018First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries
First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries.
-
Sep 21, 2018New Data at World Congress of Endourology Demonstrate the LithoVue Empower Device Improves OR Experience
New data at World Congress of Endourology demonstrate the Lithovue Empower device for kidney stone retrieval improves the OR experience.
-
Sep 17, 2018
Key data will include results from IMPERIAL trial evaluating ELUVIA drug-eluting stent and from REPRISE III study evaluating LOTUS Aortic Valve System.
-
Sep 6, 2018Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients
Acquisition expands Boston Scientific portfolio of men's health in-office procedures with SpaceOAR, an adjunctive therapy for prostate cancer patients.
-
Sep 6, 2018
Boston Scientific will participate in the upcoming healthcare conference in September 2018. A live webcast and replay will be available.
-
Aug 29, 2018
Boston Scientific will participate in the upcoming healthcare conference on Sept. 5, 2018. A live webcast and replay will be available.
-
Aug 8, 2018Acquisition to Bolster Company's Venous Therapies Portfolio within Peripheral Interventions Division
Acquisition will bolster Boston Scientific peripheral interventions portfolio with a treatment for venous obstructive disease
Aug 2, 2018CMS Grants NTAP Designation for The Sentinel® Cerebral Protection SystemBoston Scientific acquisition adds the Sentinel® Cerebral Protection System, the only device cleared to protect patients against stroke risk in TAVR procedures.